Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATOM Trial: Adjuvant tebentafusp versus observation in high-risk uveal melanoma
2023-510333-28-00Phase 3Authorised
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Nov 2024
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 12
01
Overview
Phase 3, randomised, open-label trial in intraocular melanoma comparing Adjuvant tebentafusp with Observation (2 arms). Primary endpoint: Recurrence-free survival. Planned start Nov 2024; status: authorised.
02
Drugs
tebentafusp
03
Conditions
intraocular melanoma
Beyond the preview
Go deeper on 2023-510333-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510333-28-00.